CXCL1 and metastatic malignant neoplasm in the lymph nodes: Docetaxel), which has been implicated in promoting inflammatory lymphangiogenesis and lymph node metastasis in an aggressive lung cancer model [28], and CXCL1 (p < 0.05, IgG v.